Abstract 1911P
Background
Mutations of the von Hippel-Lindau (VHL) tumor suppressor gene occur in the majority of sporadic renal-cell carcinomas (RCC). Certain VHL mutations correlate with low expression of classical HLA-I molecules and HLA-E expression that determine higher NK susceptibility. Therefore, VHL mutation maybe a predictor of responses to immune checkpoint inhibitors (ICIs). Our research aims to elucidate its mutation association with ICI efficacy.
Methods
In order to investigate the correlation between VHL mutation and ICI efficacy in the RCC, we used cBioportal to collect clinical and mutation data of 151 ICI-treated RCCs from MSKCC cohort. Gene expression and WES data of 313 samples were obtained from the TCGA database for further analysis of potential biological mechanisms between VHL-mutant and VHL-wildtype tumors. Tumor mutation burden (TMB) was calculated as the total number of somatic non-synonymous mutations per megabase in both MSKCC and TCGA cohorts. CIBERSORT algorithm was applied to infer 22 human immune cell type proportions in TCGA RCCs.
Results
In the MSKCC immunotherapy cohort, we observed 70.2% (106/151) patients harbored VHL mutation, while TCGA had lower mutation frequency with 50.5% (158/313). As indicated by Kaplan-Meier analysis, the patients with VHL mutation had significantly better OS in the MSKCC cohort (P < 0.001, median OS: 50 months vs 26 months). This link was still existing when controlling for age, sex, ICI types, TMB and metastasis in the multivariate Cox regression analysis (P = 0.005, HR = 0.45, 95%CI = 0.26-0.78). As expected, the VHL-mutant group had higher TMB than that of the VHL-wildtype group in both the MSKCC cohort (P <0.001) and TCGA cohort (P = 0.047). Immune cell analysis showed that CD8+ T cells, CD4 naïve T cells, T follicular helper cells and Macrophage M1 cells were abundant in the VHL-mutant group (both P < 0.05). These results indicated VHL-mutant tumors had an activated antitumor immune microenvironment.
Conclusions
VHL mutations might be a potential biomarker to predict the efficacy of immunotherapy for RCC. Considering the heterogeneity among the patients and other confounding factors, further prospective validation cohorts are warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1756P - Vizcan: A Swedish population-based study to address cancer outcomes using an interactive platform
Presenter: Anders Berglund
Session: Poster session 23
1757P - A real-world evaluation of the effectiveness of thermogram along with clinical breast examination in community-based breast cancer screening program
Presenter: Rahul Ravind
Session: Poster session 23
1758P - Body composition meets precision medicine: The prognostic value of sarcopenia in patients (pt) treated with Molecularly Targeted Agents (MTA)
Presenter: Cinta Hierro
Session: Poster session 23
1760P - Systematic review of quality of life (QoL) inclusion among endpoints, reporting and impact of QoL results in phase III non-inferiority trials of systemic treatments in oncology
Presenter: Jessica Paparo
Session: Poster session 23
1761P - Incidence of herpes zoster in cancer patients in Europe: A systematic review
Presenter: Inga Posiuniene
Session: Poster session 23
1762P - Are published data up-to-date? Analysis of time to publication in major oncological journals
Presenter: Pawel Sobczuk
Session: Poster session 23
1763P - The challenge for Cancer Trials Ireland (CTI) to sponsor NCI and non-EU sponsored trials in the EU
Presenter: Eibhlin Mulroe
Session: Poster session 23
1886P - Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)
Presenter: Craig Gedye
Session: Poster session 23
1887P - Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial
Presenter: Primo Lara
Session: Poster session 23